96 related articles for article (PubMed ID: 8654239)
1. [Human insulin-like growth factor I and treatment in diabetes].
Koivisto VA
Duodecim; 1994; 110(23-24):2197-201. PubMed ID: 8654239
[No Abstract] [Full Text] [Related]
2. Insulin-like growth factor I: physiology, metabolic effects and clinical uses.
Froesch ER; Hussain MA; Schmid C; Zapf J
Diabetes Metab Rev; 1996 Oct; 12(3):195-215. PubMed ID: 8959385
[No Abstract] [Full Text] [Related]
3. Therapeutic use of insulin-like growth factor I: lessons from in vivo animal studies.
Gluckman PD; Ambler GR
Acta Paediatr Suppl; 1992 Sep; 383():134-6. PubMed ID: 1458009
[No Abstract] [Full Text] [Related]
4. The chronicle of growth hormone receptor deficiency (Laron syndrome).
Rosenbloom AL
Acta Paediatr Suppl; 1992 Sep; 383():117-20. PubMed ID: 1458005
[No Abstract] [Full Text] [Related]
5. Does recombinant human insulin-like growth factor-1 have a role in the treatment of diabetes?
Dunger DB; Acerini CL
Diabet Med; 1997 Sep; 14(9):723-31. PubMed ID: 9300221
[TBL] [Abstract][Full Text] [Related]
6. Clinical uses of insulin-like growth factor I.
Hussain MA; Froesch ER
Adv Endocrinol Metab; 1995; 6():143-65. PubMed ID: 7671094
[No Abstract] [Full Text] [Related]
7. Involvement of insulin-like growth factor-I in the control of glucose homeostasis.
Clemmons DR
Curr Opin Pharmacol; 2006 Dec; 6(6):620-5. PubMed ID: 17030015
[TBL] [Abstract][Full Text] [Related]
8. Acute response to recombinant insulin-like growth factor I in a patient with Mendenhall's syndrome.
Quin JD; Fisher BM; Paterson KR; Inoue A; Beastall GH; MacCuish AC
N Engl J Med; 1990 Nov; 323(20):1425-6. PubMed ID: 2233914
[No Abstract] [Full Text] [Related]
9. Treatment with insulin glargine does not suppress serum IGF-1.
Slawik M; Schories M; Busse Grawitz A; Reincke M; Petersen KG
Diabet Med; 2006 Jul; 23(7):814-7. PubMed ID: 16842489
[TBL] [Abstract][Full Text] [Related]
10. Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates.
Williams RM; Yuen K; White D; Mallard B; Dalton RN; Acerini CL; Dunger DB
Clin Endocrinol (Oxf); 2006 Oct; 65(4):439-45. PubMed ID: 16984235
[TBL] [Abstract][Full Text] [Related]
11. Genetics and disease. Growth defect blocks cancer and diabetes.
Leslie M
Science; 2011 Feb; 331(6019):837. PubMed ID: 21330503
[No Abstract] [Full Text] [Related]
12. [Does insulin glargin (lantus) lead to a progression in diabetic retinopathy?].
Meyer CH; Kroll P; Hammes HP
Klin Monbl Augenheilkd; 2005 Apr; 222(4):353-4. PubMed ID: 15844050
[No Abstract] [Full Text] [Related]
13. Endocrine assessment, molecular characterization and treatment of growth hormone insensitivity disorders.
Savage MO; Attie KM; David A; Metherell LA; Clark AJ; Camacho-Hübner C
Nat Clin Pract Endocrinol Metab; 2006 Jul; 2(7):395-407. PubMed ID: 16932322
[TBL] [Abstract][Full Text] [Related]
14. [Acanthosis nigricans, insulin-dependent diabetes, dysmorphism: Mendenhall's syndrome?].
Prigent F; Guillon JL; Lagardère B; Gallet JP; Duprey J
Ann Dermatol Venereol; 1985; 112(9):755-6. PubMed ID: 4091429
[No Abstract] [Full Text] [Related]
15. IGF in the clinic.
Brower V
Nat Biotechnol; 1998 Jul; 16(7):601-2. PubMed ID: 9661172
[No Abstract] [Full Text] [Related]
16. An update on Laron syndrome.
Laron Z
Arch Dis Child; 1993 Mar; 68(3):345-6. PubMed ID: 8466235
[No Abstract] [Full Text] [Related]
17. Screening for type 2 diabetes in children with acanthosis nigricans.
Hardin DS
Diabetes Educ; 2006; 32(4):547-52. PubMed ID: 16873592
[TBL] [Abstract][Full Text] [Related]
18. Insulin-like growth factor-I treatment of growth disorders, diabetes mellitus and insulin resistance.
Ranke MB
Trends Endocrinol Metab; 2005; 16(4):190-7. PubMed ID: 15860416
[TBL] [Abstract][Full Text] [Related]
19. Exogenous insulin-derived Acanthosis nigricans.
Mailler-Savage EA; Adams BB
Arch Dermatol; 2008 Jan; 144(1):126-7. PubMed ID: 18209191
[No Abstract] [Full Text] [Related]
20. Insulin-like growth factor-I (lGF-l): safety and efficacy.
Laron Z
Pediatr Endocrinol Rev; 2004 Nov; 2 Suppl 1():78-85. PubMed ID: 16456486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
